A REVIEW OF TRULICITY 1.5 MG

The trial obtained both of those its Key endpoints, with semaglutide 2.4 mg demonstrating statistically significant and top-quality enhancements in liver fibrosis without any worsening of steatohepatitis, as well as resolution of steatohepatitis with no worsening of liver fibrosis in people with MASH in comparison with placebo.1If you have any opin